Generation of galectin-9-specific single-domain antibodies: new inhibitors to improve immunotherapy of cancer.

半乳糖凝集素 9 特异性单域抗体的产生：改善癌症免疫治疗的新抑制剂。

• 批准号: 476008
• 负责人: Dumoulin Alyssa
• 金额: $ 7.65万
• 依托单位: INRS - (Qubec, QC)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-11-01 至 2025-11-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=476008&lang=en
• 关键词: Breast Cancer; Galectin Inhibitors; Galectins; Glycomics; Immunotherapy; Single-Domain Antibodies

The immune system plays a key role in fighting cancer. Unfortunately, cancer cells release a number of factors that neutralize the activity of cancer-killing immune cells. Galectin-9 (GAL-9) is a small protein that is produced and released at abnormally h

免疫系统在对抗癌症中起着关键作用。不幸的是，癌细胞会释放一些因子来中和杀死癌症的免疫细胞的活性。半乳糖凝集素-9 （Galectin-9, GAL-9）是一种小蛋白，在异常h时产生并释放